VARIOUS MEDIA: Clinical trials cancer patient hails drug

Press/Media: Research

Period28 Mar 2022

Media coverage

2

Media coverage

  • TitleClinical trials cancer patient hails drug
    Media name/outletBBC News
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date28/03/22
    DescriptionDr Matthew Krebs, medical oncologist from The Christie Trust and The University of Manchester, said her tumours had since reduced by nearly 50% in three months.

    He stated this was "promising for a drug early in its development directed at KRAS mutation that has historically been very difficult to treat".

    Dr Krebs added: "It targets only a specific sub-type of KRAS mutation, and a similar drug has already been approved for patients with lung cancer.

    "There's much more work to do before this drug may be available routinely for patients, and not everyone will respond in this way, but Terri's case highlights... the potential benefits that clinical trials of new drugs can hold."
    URLhttps://www.bbc.co.uk/news/uk-england-hereford-worcester-60879065
    PersonsMatthew Krebs
  • TitleCancer-hit gran's tumours shrink in HALF after Christie Hospital drug trial breakthrough
    Media name/outletManchester Evening News
    Media typeWeb
    Country/TerritoryUnited Kingdom
    Date28/03/22
    DescriptionDr Matthew Krebs, medical oncologist from the Christie and the University of Manchester, leading on the study in the UK, said: "We are delighted at the response Terri has had to this treatment. Her scans show that her tumours have reduced by nearly 50% in just three months.

    “There’s much more work to do before this drug may be available routinely for patients, and not everyone will respond in this way, but Terri’s case highlights the importance of genetic testing in cancer patients and the potential benefits that clinical trials of new drugs can hold."

    Dr Krebs said the KRAS mutation is one of the most common mutations across a range of cancer types. The specific sub-type in Ms Hurdman’s case is KRAS G12C – the most common subgroup – which occurs in about 12% to 15% of lung cancers and 3% to 4% of bowel cancers. Around 47,000 people are diagnosed with lung cancer in the UK every year, while 43,000 are diagnosed with bowel cancer.
    URLhttps://www.manchestereveningnews.co.uk/news/greater-manchester-news/cancer-hit-grans-tumours-shrink-23514541
    PersonsMatthew Krebs

Research Beacons, Institutes and Platforms

  • Cancer

Keywords

  • bowel cancer